サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566968

乳がん検診市場：検査タイプ別、性別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年

Breast Cancer Screening Market By Test Type , By Gender By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 280 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.06円
乳がん検診市場：検査タイプ別、性別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 280 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

乳がん検診市場は2023年に29億米ドルと評価され、2024～2033年にかけてCAGR 8.7％で成長し、2033年には67億米ドルに達すると予測されています。

乳がん検診は、世界的に女性の間で最も多いがんである乳がんの早期発見を目的とした重要な公衆衛生戦略です。この予防措置の主要目的は、治療可能な早期段階でがんを発見することです。マンモグラフィは最も広く使用されている検診手段であり、定期的に使用することで乳がんによる死亡率が低下することが示されています。腫瘍を早期に発見することで、乳がん検診は治療成功の可能性を高め、生存率を向上させ、後により積極的な治療の必要性を減らすのに役立ちます。

世界の乳がん検診市場の成長は、乳がんの世界の有病率の憂慮すべき増加、早期発見法に対する認識と需要の高まりが原動力となっています。世界保健機関（WHO）が2024年3月に発表した調査によると、2022年には世界で約230万人の女性が乳がんと診断され、67万人の死亡が報告されました。さらに、政府や医療機関は、啓発キャンペーン、助成金、組織的な検診プログラムを通じて乳がん検診をますます推進しており、検診サービスへの容易なアクセスを促しています。米国疾病予防管理センターが2022年に発表した研究によると、50～74歳の女性の約76.4％が過去2年以内にマンモグラフィーを受けています。この統計は、公衆衛生キャンペーンの効果と米国全域での検診サービスの利用しやすさを反映しています。さらに、高齢女性人口の急増は市場成長に大きく寄与しています。これは、高齢女性は免疫力の低下、遺伝子変異の蓄積、乳房組織の変化により乳がん発症リスクが高いという事実に起因します。若年女性の早期検診重視の高まりと非侵襲的検診法の開発は、市場成長をさらに促進する主要動向です。しかし、乳がん検診、特に3DマンモグラフィやMRIのような高度な技術に関連する費用が高いことが、世界市場の主要な阻害要因となっています。さらに、医療インフラ、訓練を受けた専門家、移動検診ユニットの不足により、農村部や十分なサービスを受けていない地域でのアクセスが制限されていることも、市場の成長を大幅に抑制しています。逆に、デジタルマンモグラフィ、3Dマンモグラフィ、MRIなどの画像技術の革新は、乳がん検診の精度と効率を高めています。これらの進歩は、検診をより身近で信頼性の高いものにしており、世界市場拡大の好機になると期待されています。遠隔地や十分なサービスを受けていない地域での乳がん検診へのアクセスを改善するために、医療へのアクセスが限られているという懸念に対処するための移動式マンモグラフィ装置が導入されています。このような取り組みにより、近い将来、市場成長のための新たな道が開かれると予想されます。

世界の乳がん検診産業は、検査タイプ、性別、エンドユーザー、地域に区分されます。検査タイプ別では、血液マーカー検査、遺伝子検査、画像検査、免疫組織化学検査に分けられます。性別では、男性と女性に分けられます。エンドユーザー別では、専門クリニック、病院、診断センター、その他に細分化されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されます。

主要調査結果

検査タイプ別では、画像検査セグメントが2023年の市場シェアを独占しました。

性別では、女性セグメントが2023年に最大の市場シェアを示しました。

エンドユーザー別では、病院が2023年のシェアで主要セグメントとなりました。

地域別では、北米が2023年に支配的な地位を占めているが、アジア太平洋が予測期間中に最も高いCAGRを記録すると予想されています。

本レポートのカスタマイズが可能です。

  • 規制ガイドライン
  • 顧客の関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • 主要参入企業の詳細（所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 乳がん検診市場：検査タイプ別

  • 市場概要
  • 血液マーカー検査
  • 遺伝子検査
  • 画像検査
  • 免疫組織化学検査

第5章 乳がん検診市場：性別

  • 市場概要
  • 男性
  • 女性

第6章 乳がん検診市場：エンドユーザー別

  • 市場概要
  • 専門クリニック
  • 病院
  • 診断センター
  • その他

第7章 乳がん検診市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国の乳がん検診市場
    • カナダの乳がん検診市場
    • メキシコの乳がん検診市場
  • 欧州
    • 主要市場動向と機会
    • ドイツの乳がん検診市場
    • フランスの乳がん検診市場
    • 英国の乳がん検診市場
    • イタリアの乳がん検診市場
    • スペインの乳がん検診市場
    • その他の欧州の乳がん検診市場
  • アジア太平洋
    • 主要市場動向と機会
    • 日本の乳がん検診市場
    • 中国の乳がん検診市場
    • オーストラリアの乳がん検診市場
    • インドの乳がん検診市場
    • 韓国の乳がん検診市場
    • その他のアジア太平洋の乳がん検診市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルの乳がん検診市場
    • サウジアラビアの乳がん検診市場
    • 南アフリカの乳がん検診市場
    • その他のラテンアメリカ・中東・アフリカの乳がん検診市場

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第9章 企業プロファイル

  • Siemens Healthineers AG
  • Myriad Genetics, Inc.
  • Metabolomic Technologies Inc
  • Biocrates Lifesciences AG
  • A&G Pharmaceutical
  • Provista Diagnostics Inc
  • F. Hoffmann-La Roche AG
  • Volpara Health Limited
  • Quest Diagnostics Inc.
  • GE Healthcare
目次
Product Code: A324383

The breast cancer screening market was valued at $2.9 billion in 2023, and is projected to reach $6.7 billion by 2033, growing at a CAGR of 8.7% from 2024 to 2033.

Breast cancer screening is a critical public health strategy aimed at early detection of breast cancer, the most common cancer among women globally. The primary goal of this preventative measure is to identify cancer at an early stage when it is most treatable. Mammography is the most widely used screening tool, and its regular use has been shown to reduce mortality rates from breast cancer. By detecting tumors early, breast cancer screening increases the chances of successful treatment, improves survival rates, and can help to reduce the need for more aggressive treatments later on.

The growth of the global breast cancer screening market is driven by alarming increase in the global prevalence of breast cancer and rise in awareness and demand for early detection methods. According to a study published in March 2024 by the World Health Organization, approximately 2.3 million women were diagnosed with breast cancer and 670,000 deaths were reported globally in 2022. Furthermore, governments and healthcare organizations are increasingly promoting breast cancer screening through awareness campaigns, subsidies, and organized screening programs, which have encouraged easy access to screening services. According to a study published by the U.S. Centers for Disease Control and Prevention in 2022, approximately 76.4% of women aged 50-74 underwent a mammogram within the past two years. This statistic reflects the effectiveness of public health campaigns and the accessibility of screening services across the U.S. Moreover, surge in aged women population significantly contributes toward the market growth. This is attributed to the fact that aged women are at higher risk of developing breast cancer due to weakened immune system, accumulation of genetic mutations, and changes in breast tissue. Rise in emphasis on early screening in younger women and development of non-invasive screening methods are the key trends are that further fostering the market growth. However, high cost associated with breast cancer screening, particularly advanced technologies like 3D mammography or MRI, acts as a key deterrent factor of the global market. In addition, limited access in rural and underserved areas due to lack of healthcare infrastructure, trained professionals, and mobile screening units significantly restrains the market growth. On the contrary, innovations in imaging technologies, such as digital mammography, 3D mammography, and MRI, are enhancing the accuracy and efficiency of breast cancer screening. These advancements are making screening more accessible and reliable, which are expected to offer remunerative opportunities for the expansion of the global market during the market. To improve access to breast cancer screening in remote and underserved areas, mobile mammography units are being introduced to address the concern of limited access to healthcare. Such initiatives are anticipated to open new avenues for the market growth in the near future.

The global breast cancer screening industry is segmented into test type, gender, end user, and region. By test type, the market is divided into blood marker test, genetic test, imaging test, and immunohistochemistry test. According to gender, it is divided into male and female. As per end user, it is fragmented into specialty clinics, hospitals, diagnostic centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By test type, the imaging test segment dominated the market share in 2023.

According to gender, the female segment exhibited the largest market share in 2023.

As per end user, hospital emerged as the leading segment, in terms of share, in 2023.

Region wise, North America holds a dominant position in 2023; however, Asia-Pacific is expected to register highest CAGR during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global breast cancer screening market include Siemens Healthineers AG, Myriad Genetics, Inc., Metabolomic Technologies Inc, Biocrates Lifesciences AG, A&G Pharmaceutical, Provista Diagnostics Inc, F. Hoffmann-La Roche AG, Volpara Health Limited, Quest Diagnostics Inc., and GE Healthcare. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Test Type

  • Blood Marker Test
  • Genetic Test
  • Imaging Test
  • Immunohistochemistry Test

By Gender

  • Male
  • Female

By End User

  • Specialty Clinics
  • Hospitals
  • Diagnostic Centers
  • Other

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Siemens Healthineers AG
    • Myriad Genetics, Inc.
    • Metabolomic Technologies Inc
    • Biocrates Lifesciences AG
    • A&G Pharmaceutical
    • Provista Diagnostics Inc
    • F. Hoffmann-La Roche AG
    • Volpara Health Limited
    • Quest Diagnostics Inc.
    • GE Healthcare

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: BREAST CANCER SCREENING MARKET, BY TEST TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Test Type
  • 4.2. Blood Marker Test
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Genetic Test
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Imaging Test
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Immunohistochemistry Test
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country

CHAPTER 5: BREAST CANCER SCREENING MARKET, BY GENDER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Gender
  • 5.2. Male
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Female
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: BREAST CANCER SCREENING MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Specialty Clinics
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Hospitals
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Diagnostic Centers
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Other
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country

CHAPTER 7: BREAST CANCER SCREENING MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Test Type
    • 7.2.3. Market Size and Forecast, By Gender
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Breast Cancer Screening Market
      • 7.2.6.1. Market Size and Forecast, By Test Type
      • 7.2.6.2. Market Size and Forecast, By Gender
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Breast Cancer Screening Market
      • 7.2.7.1. Market Size and Forecast, By Test Type
      • 7.2.7.2. Market Size and Forecast, By Gender
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Breast Cancer Screening Market
      • 7.2.8.1. Market Size and Forecast, By Test Type
      • 7.2.8.2. Market Size and Forecast, By Gender
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Test Type
    • 7.3.3. Market Size and Forecast, By Gender
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Breast Cancer Screening Market
      • 7.3.6.1. Market Size and Forecast, By Test Type
      • 7.3.6.2. Market Size and Forecast, By Gender
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. France Breast Cancer Screening Market
      • 7.3.7.1. Market Size and Forecast, By Test Type
      • 7.3.7.2. Market Size and Forecast, By Gender
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. UK Breast Cancer Screening Market
      • 7.3.8.1. Market Size and Forecast, By Test Type
      • 7.3.8.2. Market Size and Forecast, By Gender
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Italy Breast Cancer Screening Market
      • 7.3.9.1. Market Size and Forecast, By Test Type
      • 7.3.9.2. Market Size and Forecast, By Gender
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. Spain Breast Cancer Screening Market
      • 7.3.10.1. Market Size and Forecast, By Test Type
      • 7.3.10.2. Market Size and Forecast, By Gender
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Breast Cancer Screening Market
      • 7.3.11.1. Market Size and Forecast, By Test Type
      • 7.3.11.2. Market Size and Forecast, By Gender
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Test Type
    • 7.4.3. Market Size and Forecast, By Gender
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Breast Cancer Screening Market
      • 7.4.6.1. Market Size and Forecast, By Test Type
      • 7.4.6.2. Market Size and Forecast, By Gender
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. China Breast Cancer Screening Market
      • 7.4.7.1. Market Size and Forecast, By Test Type
      • 7.4.7.2. Market Size and Forecast, By Gender
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. Australia Breast Cancer Screening Market
      • 7.4.8.1. Market Size and Forecast, By Test Type
      • 7.4.8.2. Market Size and Forecast, By Gender
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. India Breast Cancer Screening Market
      • 7.4.9.1. Market Size and Forecast, By Test Type
      • 7.4.9.2. Market Size and Forecast, By Gender
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. South Korea Breast Cancer Screening Market
      • 7.4.10.1. Market Size and Forecast, By Test Type
      • 7.4.10.2. Market Size and Forecast, By Gender
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Breast Cancer Screening Market
      • 7.4.11.1. Market Size and Forecast, By Test Type
      • 7.4.11.2. Market Size and Forecast, By Gender
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Test Type
    • 7.5.3. Market Size and Forecast, By Gender
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Breast Cancer Screening Market
      • 7.5.6.1. Market Size and Forecast, By Test Type
      • 7.5.6.2. Market Size and Forecast, By Gender
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. Saudi Arabia Breast Cancer Screening Market
      • 7.5.7.1. Market Size and Forecast, By Test Type
      • 7.5.7.2. Market Size and Forecast, By Gender
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. South Africa Breast Cancer Screening Market
      • 7.5.8.1. Market Size and Forecast, By Test Type
      • 7.5.8.2. Market Size and Forecast, By Gender
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Breast Cancer Screening Market
      • 7.5.9.1. Market Size and Forecast, By Test Type
      • 7.5.9.2. Market Size and Forecast, By Gender
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Siemens Healthineers AG
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Myriad Genetics, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Metabolomic Technologies Inc
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Biocrates Lifesciences AG
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. A&G Pharmaceutical
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Provista Diagnostics Inc
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. F. Hoffmann-La Roche AG
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Volpara Health Limited
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Quest Diagnostics Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. GE Healthcare
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments